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Overexpression of complement inhibitor Crry does not pre-
vent cryoglobulin-associated membranoproliferative glomeru-
lonephritis.
Background. Mice overexpressing thymic stromal lym-
phopoietin (TSLP) develop mixed cryoglobulinemia with re-
nal disease closely resembling human cryoglobulin-associated
membranoproliferative glomerulonephritis (MPGN), includ-
ing glomerular deposits of immunoglobulins and comple-
ment. We assessed the effect of complement inhibition
through overexpression of Crry (complement receptor-1 re-
lated gene/protein Y), which blocks the classic and alternative
pathway of complement activation through inhibition of the
C3 convertase, in cryoglobulinemia-associated immune com-
plex glomerulonephritis.
Methods. TSLP transgenic mice were crossbred with animals
overexpressing Crry. Mice were sacrificed after 50 days (fe-
males) or 120 days (males), and kidneys, blood, and urine were
collected from seven mice of each experimental group (wild
type, Crry transgenic, TSLP transgenic, and Crry/TSLP doubly
transgenic).
Results. TSLP/Crry doubly transgenic animals demonstrated
expected serum levels of Crry. Renal involvement, both in TSLP
transgenic and TSLP/Crry doubly transgenic animals, was char-
acterized by glomerular matrix expansion, macrophage influx,
activation of mesangial cells, and deposition of immunoglobu-
lins and complement. Overexpression of Crry did not result in
significant improvement of renal pathology or laboratory find-
ings. Expression of recombinant soluble Crry was confirmed by
enzyme-linked immunosorbent assay (ELISA) in Crry trans-
genic animals. However, formation of the membrane attack
complex C5b-9 as a marker of terminal active complement com-
ponents and represented by glomerular C9 staining could not
be inhibited in Crry transgenic TSLP mice.
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Conclusion. These results indicate that overexpression of
Crry was not sufficient to prevent renal injury in TSLP trans-
genic mice. We suggest that the inhibitory capacity of Crry may
be overwhelmed by chronic complement activation. Further
studies need to address the role of complement in cryoglobu-
linemic glomerulonephritis before therapeutic complement in-
hibition can be attempted.
Cryoglobulins are immunoglobulins (Ig) or immune
complexes that precipitate in the cold and redissolve
after rewarming [1]. The current classification of cryo-
globulins distinguishes three types. Type I cryoglobulins
consist of monoclonal immunoglobulins, and are usually
associated with hematologic disorders. Mixed cryoglob-
ulins, types II and III, are immune complexes composed
of either a monoclonal IgM with rheumatoid factor ac-
tivity that binds to polyclonal IgG (type II), or a mixture
of polyclonal IgM and polyclonal IgG (type III) [1, 2].
Typical manifestations of cryoglobulinemia include vas-
culitis, arthralgia, skin purpura, and can include specific
organs such as kidney, central nervous system, gut, and,
rarely, the lung [3, 4]. About one third of patients de-
velop renal disease that is histologically characterized
by a membranoproliferative glomerulonephritis with dis-
tinctive features of macrophage influx, intracapillary
deposits of cryoglobulin aggregates, microtubular ap-
pearance of glomerular immune deposits as revealed in
ultrastructural studies in some cases, and at times vasculi-
tis [5–7].
We have recently described a mouse model of cryo-
globulinemic glomerulonephritis in which the overex-
pression of thymic stromal lymphopoietin (TSLP), a
cytokine that promotes B-cell development, leads to
the production of large amounts of type III cryoglob-
ulins [8]. TSLP transgenic mice develop a systemic
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inflammatory disease that involves the skin, lungs,
liver, and spleen. Renal pathology closely resembles
human cryoglobulin-associated membranoproliferative
glomerulonephritis (MPGN). Glomeruli show suben-
dothelial and mesangial immune deposits, increased
glomerular matrix, glomerular macrophage influx, and
occlusion of capillary loops by periodic-acid Schiff (PAS)-
positive material that ultrastructurally is shown to be
immune complexes with microtubular organization. Im-
munofluorescence displays large glomerular deposits of
immunoglobulins (IgG, IgM, IgA) and the complement
component C3.
Complement activation plays an important role in
a variety of glomerular injuries, and its regulation is
critical for the preservation of renal integrity [9, 10].
Although complement usually acts as a host defense
mechanism, inappropriate activation of the complement
cascade can lead to renal injury via the generation of
chemotactic factors, and by insertion of the membrane
attack complex C5b-9 (MAC) into the membranes of res-
ident glomerular cells, which can then lead to cellular
activation or injury with subsequent release of inflam-
matory mediators [9, 11]. To avoid these undesirable re-
sults of complement activation, nature exploits a variety
of regulatory mechanisms that act on the formation of
the C3/C5 convertase step of the complement cascade
or on the assembly of the membrane attack complex
[12]. The rodent Crry protein is a membrane-bound com-
plement control factor that inhibits the cleavage of C3
into its active metabolites, and so blocks the downstream
complement cascade of both the classic and the alterna-
tive pathway of complement activation [13–16]. Overex-
pression of Crry has been shown to protect mesangial
cells from complement-mediated injury in vitro [17], and
transgenic mice engineered to overexpress recombinant
soluble Crry have been demonstrated to be protected
against the antibody-induced glomerular injury that oc-
curs in nephrotoxic serum nephritis (NSN) and genetic
models of lupus-associated renal disease [18–20].
In this study we assessed the impact of chronic com-
plement inhibition by Crry on the development of im-
mune complex–mediated kidney disease in a rodent
model of cryoglobulin-associated membranoprolifera-
tive glomerulonephritis.
METHODS
Animal study and experimental design
The experimental protocol for this study was reviewed
and approved by the Animal Care Committee of the
University of Washington in Seattle. Mice transgenic for
TSLP have been previously described in detail [8]. Ani-
mals overexpressing the complement inhibitor Crry were
crossbred with TSLP transgenic mice to generate doubly
transgenic animals.
Both strains were backcrossed onto a C57BL/6 back-
ground. The animals were housed in a specific pathogen-
free facility at the University of Washington with a fixed
12 hours light cycle, constant temperature of 25◦C, and
water and food ad libidum. At three weeks of age mice
were weaned and genotyped as described previously [8,
18]. Experimental groups consisted of wild-type C57BL/6
mice, TSLP transgenic, Crry transgenic, and TSLP/Crry
doubly transgenic animals, with 7 mice in each group.
Female mice were sacrificed at 50 days of age, while males
were kept for 120 days because of slower progression of
the disease [8]. At the end of the study mice were anes-
thetized, blood was drawn by cardiac puncture, and or-
gans were collected. Renal tissue was snap frozen in liquid
nitrogen or stored in either 10% neutral buffered forma-
lin, methyl Carnoy’s solution (60% methanol, 30% chlo-
roform, 10% acetic acid), or half-strength Karnovsky’s
solution (1% paraformaldehyde and 1.25% glutaralde-
hyde in 0.1 mol/L Na cacodylate buffer, pH 7.0) for later
use.
Tissue preparation and histologic staining
Tissues fixed in formalin and methyl Carnoy’s solu-
tion were embedded in paraffin using routine protocols.
Paraffin-embedded materials were sectioned at 4 lm for
routine staining with hematoxylin and eosin, PAS, and
immunohistochemistry. Two-lm thick sections were used
for periodic-acid methenamine silver stains (PAM). Im-
munofluorescence was performed on snap frozen kid-
neys, sectioned at 6 lm, and fixed in ice-cold acetone for
10 minutes.
Immunohistochemistry
For immunohistochemical staining, histologic sections
of paraffin-embedded tissue were deparaffinized in xy-
lene and rehydrated in graded ethanol. When required,
antigen retrieval was performed by steam heating the
tissue sections in Antigen Unmasking Solution (Vector
Laboratories, Burlingame, CA, USA). Endogenous per-
oxidases were blocked in 3% hydrogen peroxide, and
endogenous biotin was blocked using the Avidin/Biotin
blocking kit (Vector Laboratories). The slides were then
incubated with the primary antibody diluted in 1% bovine
serum albumin (BSA) in phosphate-buffered saline so-
lution (PBS) for one hour at room temperature. After
that the sections were washed with PBS and immersed in
the appropriate biotinylated secondary antibody, again
diluted in PBS with 1% BSA. Signal amplification was
performed using the ABC-Elite Reagent (Vector Lab-
oratories). 3,3′-diaminobenzidine with nickel enhance-
ment was used as chromogen, which results in a black
color product. The slides were counterstained with
methyl green, dehydrated, and then coverslipped.
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A rat MAC-2 antibody (Cederlane; Ontario, Canada)
was used to detect macrophages as described previously
[21]. A mouse-adsorbed antirat antibody (Vector Lab-
oratories) was utilized as secondary antibody. For the
detection of mesangial cell activation and smooth
muscle–like transformation, a a-smooth muscle actin an-
tibody (clone 1A4; Dako, Carpenteria, CA, USA, as
previously described [22]) was used. In this case, the sec-
ondary antibody was an anti-IgG2a antibody (Pharmin-
gen, San Diego, CA, USA). Cellular proliferation was
assessed using a mouse monoclonal Ki67 antibody (pre-
viously described in [23]) (Pharmingen) with the Dako
Animal Research kit. A goat polyclonal antihuman colla-
gen IV antibody (Southern Biotechnology, Birmingham,
CA, USA) was used for the staining of extracellular ma-
trix [24]. A biotinylated rabbit antigoat antibody was ap-
plied as secondary antibody (Vector Laboratories).
For immunofluorescence, acetone-fixed sections were
rehydrated in PBS and then incubated with fluorescein-
conjugated antibodies against IgG, IgA, IgM, com-
plement factor C3 (all from Cappel Pharmaceuticals,
Aurora, OH, USA), or C9; antisera against rat C9, which
cross-reacts with mouse complement factor 9, was gener-
ously provided by Paul Morgan, University of Wales Col-
lege of Medicine, previously described in [25, 26]. Slides
were coversliped with Vectashield mounting medium
(Vector Laboratories) and viewed with a Zeiss fluores-
cence microscope (Thornwood, NY, USA).
Laboratory data
Urinary protein excretion was tested with urine test
strips (Uristix; Bayer, Elkhart, IN, USA) and assessed
semiquantitatively on a scale of 0 to 4. Blood urea nitro-
gen (BUN) was measured using a standard clinical chem-
istry analyzer (LX-20; Beckman Laboratories, Brea, CA,
USA). Serum Crry levels were assessed by enzyme-linked
immunosorbent assay (ELISA) as previously described
[18]. Plasma C3 levels were determined by ELISA as de-
scribed previously [27].
Analytical methods and statistics
Glomerular cellularity was assessed in tissue sections
stained with hematoxylin and eosin. Fifteen random
glomerular cross sections (gcs) were photographed with
a digital camera (Olympus DP11; Olympus America,
Melville, NY, USA). Pictures were imported into the Im-
age Pro Plus Software (Media Cybernetics, Silver Spring,
MD, USA) and glomerular cellularity and glomerular
tuft area were quantified. The same method was used
to quantify extracellular matrix in PAM-stained slides
and in sections stained for collagen IV by immunohisto-
chemistry. The number of Ki67-positive cells and MAC-
2–expressing cells was assessed by counting positive cells
in at least 40 random glomerular cross sections. Alpha-
Table 1. Kidney function in experimental animals
TSLP
transgenic/
TSLP Crry Crry
Wild-type transgenic transgenic transgenic
Females
BUN mg/mL 23.2 ± 5.6 27.7 ± 7.3 23.0 ± 5.8 27.2 ± 4.0
Protein excretion 0.8 ± 0.4 0.8 ± 0.3 0.8 ± 0.6 0.8 ± 0.3
Males
BUN mg/mL 23.2 ± 3.5 26.3 ± 3.5 28.0 ± 2.9 26.5 ± 3.6
Protein excretion 0.9 ± 0.2 1.3 ± 0.6 0.9 ± 0.3 1.3 ± 0.7
Data expressed as mean ± standard deviation. Proteinuria assessed by
dipstick analysis: 1 = 30 mg/dL; 2 = 100 mg/dL. The results show no statistically
significant differences between groups.
smooth muscle actin expression of mesangial cells was
assessed semiquantitatively by scoring the amount of
glomerular expression on a scale from 0 (no stain) to
4 (strong expression in the whole mesangial area) as
described previously [28]. The fluorescence intensity of
cryosections stained for immunoglobulins and comple-
ment was assessed in a similar way by describing the fluo-
rescence intensity on a scale from 0 (negative) to 3 (strong
staining) as previously described [8]. All morphometric
analysis was performed by an examiner blinded for the
origin of the sample.
Statistical analysis was performed using the InStat pro-
gram (Version 3.0; Intuitive Software for Science, San
Diego, CA, USA). Groups were compared using the non-
parametric Kruskal-Wallis test and Dunn’s multiple com-
parison test. All values are expressed as mean ± standard
deviation. P <0.05 was considered statistically significant.
RESULTS
Kidney function remains unaffected by the disease
and by complement inhibition
Excretory renal function was determined by measure-
ment of BUN, and urinary protein excretion was assessed
by dipstick tests. The four groups of animals tested did
not demonstrate significant differences in renal function
or proteinuria (Table 1).
Doubly transgenic Crry/TSLP transgenic mice develop
increased glomerular matrix similar to TSLP
transgenic mice
Female TSLP transgenic mice expressed more than
twice the amount of extracellular matrix than wild-
type animals when silver stained matrix in periodic-acid
methenamine silver stained histologic sections was as-
sessed morphometrically (315 ± 62 lm2/gcs for wild-
type mice vs. 737 ± 62 lm2/gcs TSLP transgenic animals,
P < 0.01) (Table 2 and Fig. 1). This result was congru-
ent with the measurement of collagen IV, an important
component of the extracellular matrix, in which TSLP
transgenic mice showed an almost fourfold increase in
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Table 2. Glomerular morphology
TSLP
transgenic/
TSLP Crry Crry
Wild-type transgenic transgenic transgenic
Females
Cellularity cells/gcs 44 ± 6 45 ± 6 46 ± 8 50 ± 9
Cellularity cells/area 0.014 ± 0.0022 0.013 ± 0.0010 0.014 ± 0.0016 0.013 ± 0.0011
Matrix lm2/gcs 315 ± 62 737 ± 165b 372 ± 111 724 ± 184b
Matrix % of area 11 ± 2 22 ± 5b 13 ± 3 22 ± 6b
Collagen IV lm2/gcs 201 ± 27 740 ± 177c 210 ± 62 495 ± 41c
Collagen IV % of area 10 ± 2 25 ± 2b 9 ± 2 22 ± 2c
Glomerular size lm2/gcs 3135 ± 283 3349 ± 385 3123 ± 528 3538 ± 347
Males
Cellularity cells/gcs 39 ± 6 45 ± 3 40 ± 6 51 ± 8a
Cellularity cells/area 0.012 ± 0.0012 0.015 ± 0.0005 0.013 ± 0.0010 0.012 ± 0.0005
Matrix lm2/gcs 470 ± 124 879 ± 233a 509 ± 91 1004 ± 267b
Matrix % of area 16 ± 2 24 ± 7a 16 ± 2 27 ± 4b
Collagen IV lm2/gcs 240 ± 82 715 ± 124a 227 ± 29 780 ± 68b
Collagen IV % of area 9 ± 2 24 ± 4a 9 ± 1 24 ± 1a
Glomerular size lm2/gcs 3312 ± 456 3731 ± 202 3181 ± 367 4012 ± 571
Morphometric analysis of glomerular cellularity, matrix, collagen IV, and glomerular size. Data is expressed as mean ± standard deviation.
Statistical significant differences are aP < 0.05, bP < 0.01, cP < 0.001 compared to wild-type control.
Fig. 1. Glomerular morphology. Glomerular morphology in individual
experimental groups, periodic-acid methenamine silver stain. Normal
glomerular architecture in (A) a wild-type mouse and (B) a Crry trans-
genic mouse. (C) Mesangial expansion and matrix accumulation in a
thymic stromal lymphopoietin (TSLP) transgenic mouse, and (D) a
doubly (TSLP and Crry) transgenic mouse, with a glomerulus showing
increase in extracellular matrix.
area stained (740 ± 177 lm2/gcs vs. 201 ± 27 lm2/gcs
in wild-type controls, P < 0.01). The results of the mor-
phometric analysis of the staining of extracellular matrix
in male TSLP animals at the age of 4 months matched
that of the female TSLP group. Crry transgenic animals
(males and females) showed no differences in the ex-
pression and staining pattern of glomerular extracellular
matrix compared to wild-type controls (Fig. 1). Over-
expression of the complement inhibitor Crry in TSLP
transgenic mice failed to reduce extracellular matrix and
glomerular collagen IV accumulation in both genders
(Table 2 and Fig. 1).
Crry overexpression has no significant impact
on glomerular cellularity, glomerular proliferation,
and glomerular cell activation
Female mice of the different experimental groups
showed no significant differences in glomerular cellu-
larity at the age of 50 days. Male animals, kept in the
study for 120 days, had comparable number of cells per
glomerular cross section between wild-type, Crry overex-
pressing, and TSLP transgenic mice. Male doubly trans-
genic animals showed a slight increase in glomerular
cellularity per glomerular cross section compared to Crry
transgenic or wild-type mice (P < 0.05), but cellularity
per glomerular area was not significantly different from
other experimental groups (Table 2). Cellular prolifera-
tion rate, assessed as Ki67-positive cells per glomerular
cross section, was not altered in mice overexpressing the
complement inhibitor Crry, animals transgenic for TSLP
that showed membranoproliferative glomerulonephritis,
or doubly transgenic mice (data not shown).
Wild-type mice showed only occasional expression of
a-smooth muscle actin in the glomeruli (Fig. 2). Compa-
rable levels of expression were present in the glomeruli
of Crry overexpressing mice. In contrast, mice that were
transgenic for TSLP had elevated levels of glomerular a-
smooth muscle actin expression (score of 1.3 ± 0.3/gcs for
1218 Mu¨hlfeld et al: Crry in membranoproliferative glomerulonephritis
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
Al
ph
a 
sm
oo
th
 m
u
sc
le
 a
ct
in
 e
xp
re
ss
io
n/
gc
s
WT TSLP tg Crry tg TSLP tg /
Crry tgFemales Males
Fig. 2. a-smooth muscle actin expression. Semiquantitative assessment
of glomerular a-smooth muscle actin expression. Graphs depict mean
± standard deviation, with statistical significant differences between
groups marked as ∗P < 0.05 and ∗∗P < 0.01.
females and 0.9 ± 0.3/gcs for males vs. 0.3 ± 0.2/gcs and
0.3 ± 0.1/gcs for female and male control animals, respec-
tively; P < 0.01). Overexpression of Crry did not reduce
the level of mesangial activation in TSLP transgenic mice
as assessed by the degree of a-smooth muscle actin ex-
pression. Expression patterns were similar in male and
female mice.
No significant a-smooth muscle actin staining was
noted in the tubulointerstitium in any of the experimental
groups.
Complement inhibition has no effect on glomerular
macrophage influx
Wild-type mice and animals transgenic for Crry
had usually less then one glomerular macrophage per
glomerular cross section (Fig. 3). TSLP transgenic mice
displayed considerable macrophage influx, with 2.1 ± 0.7
MAC-2–positive cells/gcs for females (P < 0.01) and 1.9 ±
0.9 MAC-2–positive cells/gcs for males (P < 0.01).
TSLP and Crry doubly transgenic mice did not show
a significant reduction of macrophage influx (2.1 ± 0.7
MAC-2–positive cells/gcs for females and 1.7 ± 0.6 MAC-
2–positive cells/gcs for males).
TSLP/Crry doubly transgenic animals express Crry
Elevated plasma levels of the recombinant soluble Crry
protein were confirmed in 5 male mice of each experi-
mental group by ELISA. Due to the limited amount of
plasma available from each mouse and the consistency
with which the Crry transgene is expressed in Crry trans-
genic animals of both sexes [18], this assay was only per-
formed in male animals, which yield more blood during
Fig. 3. Immunohistochemistry for macrophages. Macrophage im-
munohistochemistry using MAC-2 antibody, methyl green counterstain.
Normal glomerulus of a (A) wild-type mouse and of a (B) Crry trans-
genic animal. (C) Mice transgenic for thymic stromal lymphopoietin
(TSLP) have prominent glomerular macrophage influx, as do mice
transgenic for TSLP and Crry, as illustrated in (D).
necropsy due to the later age at sacrifice. TSLP/Crry dou-
bly transgenic animals had the highest plasma levels of
soluble recombinant Crry that did exceed that of Crry
transgenic mice sixfold (6.1 ± 1.7 lg/mL vs. 0.9 ± 0.3 lg/
mL in TSLP/Crry and Crry transgenic animals, respec-
tively, P < 0.001). No detectable Crry levels were present
in TSLP transgenic mice and wild-type control animals.
Overexpression of Crry has no effect on plasma
C3 levels and glomerular complement or
immunoglobulin deposition
Plasma complement factor C3 was measured to further
clarify the role of complement in this model of TSLP-
induced cryoglobulin-associated membranoproliferative
glomerulonephritis. Approximately 60% of patients with
cryoglobulinemia show decreased levels of early com-
plement factors like C3 in their serum. However, the
degree of hypocomplementemia correlates poorly with
the cryocrit levels or the presence of clinical symptoms
[4]. TSLP transgenic mice did not demonstrate a signifi-
cant decrease of the complement factor C3 as determined
by measurement of plasma C3 levels (Fig. 4). The intro-
duction of the Crry transgene itself did not influence the
amount of plasma C3 in control animals, and also left
plasma C3 levels unaffected in TSLP transgenic mice.
Wild-type control mice had only minimal glomeru-
lar deposition of immunoglobulins (IgG, IgM, and IgA)
(Fig. 5), in accord with previous findings. In contrast, mice
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Fig. 4. Plasma C3 levels. Plasma levels of C3 were measured by
enzyme-linked immunosorbent assay (ELISA) in female and male an-
imals. Data is presented as mean ± standard deviation. No statistically
significant differences were observed.
transgenic for TSLP showed strong glomerular staining
for immunoglobulins. As expected, Crry overexpressing
animals had no or only small glomerular depositions of
immunoglobulins. Overexpression of Crry in TSLP trans-
genic animals did not lead to a reduction in glomerular
deposits of immunoglobulins.
Immunofluorescence staining for C3 and C4 was per-
formed to assess the role of early components of the
complement cascade in the pathogenesis of cryoglobulin-
associated MPGN in TSLP transgenic mice. Wild-type
and Crry transgenic animals showed only minimal
glomerular deposition of C3. TSLP transgenic mice and
TSLP/Crry doubly transgenic animals had significantly
stronger glomerular staining for C3. In contrast, glomeru-
lar deposition of C4 was consistently high even in wild-
type or Crry transgenic animals, and did not increase in
TSLP transgenic mice. It was not affected, either, by the
overexpression of Crry in these animals (Fig. 5).
In addition, the glomerular deposition of the comple-
ment factor C9 was assessed to directly measure medi-
ators of glomerular damage. C9 is generally believed to
be a good representative for the presence of the mem-
brane attack complex C5b-9 (MAC), a complex of later
factors in the complement cascade that is thought to be
a direct mediator of complement induced cellular injury
by inserting into the cellular membranes and leading to
lytic or sublytic damage. Wild-type and Crry transgenic
mice showed only negligible amounts of glomerular C9
deposition while TSLP transgenic mice had increased
glomerular deposition of C9, demonstrating that the for-
mation of the MAC may be involved in the induction of
cryoglobulin-associated renal injury (Fig. 5). However,
the expression of the Crry transgene was not sufficient to
reduce glomerular C9 deposition, indicating that the com-
plement inhibitory action of Crry may be overwhelmed
by the high levels of circulating immune complexes in
TSLP transgenic mice.
DISCUSSION
Activation of the complement system plays an impor-
tant role in the initiation and maintenance of a variety of
glomerular injuries. Glomerular damage in cryoglobulin-
associated membranoproliferative glomerulonephritis in
humans and rodents is conferred by large numbers of
circulating immunoglobulins consisting of monoclonal
or polyclonal IgG and IgM, which deposit in suben-
dothelial locations within the capillary walls or aggre-
gate in capillary lumina [8]. Complement activation
by these immune complexes is thought to con-
tribute to the pathogenesis of the disease because
patients with cryoglobulin-associated membranoprolifer-
ative glomerulonephritis typically show low serum levels
of complement C4 and CH50, as well as normal to low
levels of C3, indicating activation of mainly the classic
complement pathway [29]. Renal biopsies of affected
individuals also show large glomerular deposits of im-
munoglobulins together with complement components
[4, 8, 29]. We recently described a mouse model of
cryoglobulinemic glomerulonephritis in TSLP trans-
genic mice, which demonstrated a reproducible renal le-
sion characterized by glomerular deposition of immune
complexes and complement component C3, glomeru-
lar infiltration by monocytes/macrophages, and increased
glomerular matrix formation. We hypothesized that acti-
vation of complement by immune complexes was a key
amplification step in this form of glomerular injury. In
this scenario, complement activation should lead to the
recruitment of monocytes/macrophages, activation and
proliferation of glomerular cells, and, as disease progres-
sion ensues, increased matrix formation. To test this role
of complement in TSLP transgenic mice, we used a ge-
netically engineered mouse strain to inhibit complement
activation.
Natural inhibition of undesired complement activa-
tion in mammals is regulated by circulating plasma
and membrane-bound complement inhibitors that either
block the assembly of the membrane attack complex
or act at the level of C3/C5 convertases, thus inhibit-
ing the classic and alternative pathway similarly. Crry, a
membrane-bound complement inhibitor, represents the
rodent functional analog for human decay accelerating
factor (DAF) and membrane cofactor protein (MCP) and
blocks complement activation at the level of the C3 con-
vertase [16, 30]. Its physiologic importance in regulating
complement activation in renal disease models in vivo
has been demonstrated by the use of anti-Crry antibod-
ies, which lead to the suppression of intrinsic Crry and
result in tubulointerstitial injury in healthy control rats
[31]. Inhibition of Crry by anti-Crry antibodies has also
been shown to aggravate renal injury in the anti-Thy 1
nephritis model of rats where it resulted in more severe
mesangiolysis, more prominent cellular infiltration, and
increased complement deposition in glomeruli of affected
1220 Mu¨hlfeld et al: Crry in membranoproliferative glomerulonephritis
–1.00
0.00
1.00
2.00
3.00
4.00
G
lo
m
er
u
la
r C
3
WT
TS
LP
 tg
Crr
y t
g
TS
LP
 tg 
/
Crr
y t
g
–1.00
0.00
1.00
2.00
3.00
4.00
G
lo
m
er
u
la
r I
gG
WT
TS
LP
 tg
Crr
y t
g
TS
LP
 tg 
/
Crr
y t
g
0.0
1.0
2.0
3.0
4.0
G
lo
m
er
u
la
r C
4
WT
TS
LP
 tg
Crr
y t
g
TS
LP
 tg 
/
Crr
y t
g
0.00
1.00
2.00
3.00
4.00
G
lo
m
er
u
la
r I
gM
WT
TS
LP
 tg
Crr
y t
g
TS
LP
 tg 
/
Crr
y t
g
0.00
1.00
2.00
3.00
4.00
G
lo
m
er
u
la
r I
gA
WT
TS
LP
 tg
Crr
y t
g
TS
LP
 tg 
/
Crr
y t
g
0.0
1.0
2.0
3.0
4.0
G
lo
m
er
u
la
r C
9
WT
TS
LP
 tg
Crr
y t
g
TS
LP
 tg 
/
Crr
y t
g
Females Males Females Males
Females Males Females Males
Females Males
Females Males
Fig. 5. Immunoglobulins and complement. Semiquantitative assessment of glomerular immunoglobulin and complement deposition. Graphs show
mean ± standard deviation, with statistical significant differences between groups expressed as ∗P < 0.05 and ∗∗P < 0.01.
animals [32]. The reduction of Crry expression via anti-
sense oligodeoxynucleotides augmented tubulointersti-
tial injury in puromycin-aminonucleoside nephritis [33].
A soluble recombinant form of Crry with an extended
half-life was created by fusing the Crry protein to mouse
IgG1 hinge, CH2, and CH3 domains. The complement-
inhibitory activity of this construct has been demon-
strated in complement activation assays in vitro, as well
as in nephrotoxic serum nephritis in vivo, where it was
shown to diminish renal injury [34]. A transgenic mouse
strain has been developed that overexpresses soluble
recombinant Crry to achieve continuous complement
pathway blockade [18]. Previous studies with these an-
imals have been encouraging by showing that transgenic
mice were protected against several forms of renal in-
jury, including nephrotoxic serum nephritis, antibody-
induced renal failure, and renal function impairment
in lupus-associated kidney disease [18–20]. These mice
were used in our study to test whether the benefits
of Crry overexpression could be extended to an estab-
lished model of immune complex–mediated glomeru-
lonephritis. A surprising finding of this study is that
inhibition of complement activation by high levels of cir-
culating recombinant soluble Crry in TSLP transgenic
mice with cryoglobulin-associated membranoprolifera-
tive glomerulonephritis fails to prevent or significantly
ameliorate the injury ensuing from immune complex and
complement deposition. Doubly transgenic mice did not
show a decrease in mesangial cell activation, glomeru-
lar matrix accumulation, or glomerular macrophage in-
flux. Circulating levels of the complement component C3
and glomerular deposition of immunoglobulins and com-
plement C3 were not influenced by elevated circulating
levels and local expression of Crry. Similarly, glomerular
deposition of C9, an established marker for membrane at-
tack complex (MAC, C5b-9) formation, which indicates
terminal complement activation, was high in TSLP trans-
genic mice and was not reduced in Crry/TSLP doubly
transgenic animals, pointing to a conclusion that comple-
ment inhibition may not have been complete.
High levels of circulating Crry in mice singly transgenic
for this molecule have been described, and we confirmed
such levels were also present in our doubly transgenic
mice [18]. The functional efficacy of recombinant soluble
Crry from serum and urine of the Crry transgenic mice has
been previously demonstrated to block complement ac-
tivation in vitro [18]. However, we do not know whether
a further increase of complement inhibitor levels, such
as by adding treatment of the doubly transgenic ani-
mals with Crry-Ig, would have altered the disease. Inter-
estingly, doubly transgenic mice had significantly higher
plasma levels of the recombinant protein than mice trans-
genic for Crry alone. It seems unlikely that this is the
result of impaired excretion of the protein into the
urine because cryoglobulinemic glomerulonephritis usu-
ally does not lead to a significant decline in renal function.
It could be speculated that Crry forms complexes with
circulating immune complexes, which then inhibits its
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excretion, leading to higher plasma levels, but the actual
basis for the observed increase in levels is not known.
Three possible explanations for the failure of Crry to
protect TSLP mice from glomerulonephritis deserve con-
sideration. The first of these is the strong and chronic
stimulation of the complement system by high levels of
serum cryoglobulins that might have overwhelmed the
inhibitory capacity of Crry. This was directly evaluated
by measurements of circulating C3, and by assessment
of the terminal complement component C9, a significant
part of the membrane attack complex C5b-C9, which
should be inhibited or reduced if Crry overexpression
would lead to sufficient complement inhibition. Circu-
lating levels of C3 revealed no significant differences
between any of the experimental groups. This finding in-
dicates the chronic immune complex deposition occur-
ring in TSLP mice did not cause a process of increased
complement consumption that could not be counterbal-
anced by the overexpression of Crry. Glomerular C9 de-
position was increased in TSLP transgenic mice, but did
not show a reduction in TSLP/Crry doubly transgenic
mice, pointing to a conclusion that complement inhibition
by Crry may not have been enough to inhibit the forma-
tion of complement effector products like the membrane
attack complex that leads to subsequent cellular injury.
With this in mind, it can be noted that in other studies of
the efficacy of Crry in models of renal injury [e.g., nephro-
toxic serum nephritis (NSN) and antibody-induced renal
failure], the protective effect that was demonstrated in-
volved a rather short and time-limited stimulus to the
complement system. Renal morphology and function in
these models was not assessed longer than 30 hours after
initiation of disease. At that 30-hour time point a dif-
ference in C3 deposition between transgenic and wild-
type animals in NSN was already lost, indicating that the
protective capacity of Crry diminished over time. Such
may have been the case in our long-term model. A study
of anti-GBM glomerulonephritis suggests that the role
of complement in the acute phase of injury might differ
from its function in more chronic disease processes. Defi-
ciency of C3 in mice with anti-GBM glomerulonephritis
led to reduced injury in the early heterologous phase of
the disease while C3−/− animals had heavier proteinuria
and more severe uremia in the late autologous phase after
14 days [35]. The only study that used complement inhibi-
tion in a model of chronic kidney injury involving comple-
ment activation was performed in MRL/lpr lupus mice,
which develop a proliferative glomerulonephritis [19].
Overexpression of Crry in these mice led to an improve-
ment in renal function and a survival benefit along with a
reduction in glomerular C3 deposition. However, clinical
benefits were disassociated from morphologic manifes-
tations of the disease and renal pathology. The extent of
glomerular immunoglobulin deposition, the amount of
glomerulosclerosis, the number of glomerular crescents,
and the glomerulonephritis scores were unaltered in lu-
pus mice with and without complement inhibition. This
is consistent with the data obtained in our study.
A second reason for the relative lack of efficacy of com-
plement inhibition by Crry might be that the degree of
complement inhibition may have been incomplete and
may have been insufficient to significantly alter the dis-
ease. Measures of complement activity performed in this
study were serum levels of C3 and renal deposition of C3,
C4, and C9, as determined by immunofluorescence mi-
croscopy. We sought to expand our measures of comple-
ment activation, but the low hemolytic activity of mouse
serum precluded utilizing a conventional assay of CH50,
and values for animals from all experimental groups were
under or at the lower detection limit. We therefore can-
not confirm that overexpression of Crry had no effect
on complement activation, but the comparable levels of
C3 in plasma of wild-type control animals, TSLP mice,
and doubly transgenic mice are a strong indication that
serum complement activation was largely unaffected by
the documented overexpression of the transgene. A per-
sistent conundrum is that Crry transgenic animals can
be protected from immune complex–mediated disease in
some injury models, despite an inability to demonstrate
an effect on complement activation in the serum. Such
observations suggest complement could still be an impor-
tant mediator of the immune injury in these animals, but
the mechanisms of this mediation are not readily appar-
ent and do not readily conform to traditional paradigms
of systemic complement activation and amplification of
injury, but instead are related to local effects of comple-
ment inhibition. In any case, our findings suggest that
the beneficial effects of Crry inhibition on renal immune
injury, whether or not an effect on systemic complement
activation can be demonstrated, may be animal strain and
model system–dependent and were not effective in this
model of cryoglobulinemic glomerulonephritis.
A third explanation, which challenges the usual
paradigm by which complement activation amplifies im-
mune complex–mediated injury, is that complement may
have a protective role in the pathophysiology of the dis-
ease. In this scenario, the beneficial effects of complement
in promoting the disposal of immune complexes over-
ride the effects of amplification of inflammatory cascades.
The validity of this paradigm is supported by studies
performed in rats with chronic serum sickness glomeru-
lonephritis, in which the depletion of plasma complement
led to a virtual cessation of glomerular immune com-
plex removal [36]. In humans with lupus, it is known that
naturally occurring deficiencies of complement compo-
nents increase the susceptibility to this immune complex–
mediated disease, supporting the idea that complement
may be protective in some forms of glomerulonephritis.
Our study is inconclusive with regard to this last possibil-
ity because we were unable to demonstrate alterations in
1222 Mu¨hlfeld et al: Crry in membranoproliferative glomerulonephritis
circulating C3 levels or complement deposition with Crry
overexpression.
A final consideration comes from data from other
forms of immune complex–mediated diseases, such as the
Arthus reaction or passive immune complex alveolitis,
which have indicated a prominent role for mediation of
disease by Fc receptors, rather than complement activa-
tion, by demonstrating that tissue injury is unchanged in
complement-deficient mice, while Fcc receptor–deficient
animals were protected from the disease [37, 38]. Lend-
ing credence to this possibility, we have preliminary data
that one such receptor, the FccRIIb, is an important me-
diator of glomerular injury in the TSLP model, and that
deletion of this receptor causes significant aggravation of
the glomerulonephritis [39].
CONCLUSION
Complement inhibition by overexpression of recombi-
nant soluble Crry in a mouse model of chronic glomeru-
lonephritis secondary to immune complex deposition
failed to demonstrate significant improvement in mor-
phologic parameters of injury, despite demonstration of
increased serum levels of Crry, most likely because com-
plement activation was too strong and overwhelmed the
inhibitory capacity of Crry, or because complement in-
hibition by Crry was incomplete. This study indicates
the importance of defining which glomerular lesions
are driven by complement activation and might there-
fore benefit from therapeutic complement inhibition. An
immune complex deposition process with local activa-
tion of complement is not sufficient to define such a
lesion.
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